Comparison of Enoxaparin Dosing to Achieve Anti-Factor Xa Thromboprophylaxis Levels in Super Morbidly Obese Patients undergoing Bariatric Surgery: A Prospective Randomized Controlled trial

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20221227001

Enrollment

Registered

2022-12-27

Start date

2022-09-09

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enoxaparin dosing to achieve anti-Factor Xa thromboprophylaxis levels in super morbidly obese patients undergoing bariatric surgery Bariatric surgery, Thromboprophylaxis, Enoxaparin, Anti-Factor Xa, Super morbid obesity

Interventions

Enoxaparin 80 mg subcutaneously 12 hrs before surgery,Enoxaparin 60 mg subcutaneously 12 hrs before surgery

Experimental Drug,Active Comparator Drug

Enoxaparin 80 mg,Enoxaparin 60 mg

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Obese patients with BMI over or equal 50 kg/m2, 2. Age between 18-60 years

Exclusion criteria

Exclusion criteria: 1. BMI less than 50 kg/m2, 2. Severe co-morbidities, 3. Current used of anticoagulants, 4. Patient with creatinine clearance <30 ml/min

Design outcomes

Primary

Measure	Time frame
Anti-factor Xa levels 4 hrs, 12 hrs after administration IU/ml	—

Secondary

Measure	Time frame
DVT 30-days postoperation Duplex ultraosonography,Perioperative blood loss Intraoperative and postoperative period ml	—

Countries

Thailand

Contacts

Public ContactPattharasai Kachornvitaya

Faculty of Medicine, Chulalongkorn University

pk_first17@hotmail.com0890354746

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026